IP Library Granted Patent US 9,675,548
Granted Patent B2
US 9,675,548 · App. 10/565,706 · Granted Jun 13, 2017

Orally dissolving films

Inventor: Li-Lan Chen (Parsippany, NJ)
Assignee: GlaxoSmithKline, LLC
A61K9/0056A61K9/006A61K9/7007A61K31/4439A61K31/465A61K31/724A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,675,548
App. No.
10/565,706
Granted
Jun 13, 2017
Kind
B2
Abstract

Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein.

Claims (21)

1. An orally dissolving film composition formed by the combination of

a polymer consisting of a pre-neutralized enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinylacetate phthalate, poly(ethylacrylate -methacrylic acid) copolymer, shellac, hydroxypropyl methylcellulose acetate succinate, poly (methyl vinyl ether/maleic acid) monoethyl ester, and poly(methyl vinyl ether/maleic acid) n-butyl ester and mixtures thereof;

at least one alkaline buffering agent; and

nicotine oil;

wherein the orally dissolving film is effective to reduce nicotine cravings within about 10 minutes through transbuccal absorption of nicotine.

2. The film composition of claim 1 wherein the pre-neutralized enteric polymer is poly(ethylacrylate-methacrylic acid) copolymer.

3. The film composition of claim 1 wherein said alkaline buffering agent is selected from the group consisting of sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate dibasic, potassium phosphate tribasic, calcium carbonate, magnesium carbonate, sodium hydroxide, magnesium hydroxide, potassium hydroxide, aluminium hydroxide, and mixtures thereof.

4. The film composition of claim 1 further comprising a plasticizer.

5. A method of reducing or eliminating tobacco consumption by an individual in need thereof by administering to the individual an orally dissolving film formed by the combination of polymer consisting of an enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinylacetate phthalate, poly(ethylacrylate -methacrylic acid) copolymer, shellac, hydroxypropyl methylcellulose acetate succinate, poly (methyl vinyl ether/maleic acid) monoethyl ester, and poly(methyl vinyl ether/maleic acid) n-butyl ester and mixtures thereof, selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinylacetate phthalate, poly(ethylacrylate -methacrylic acid) copolymer, shellac, hydroxypropyl methylcellulose acetate succinate, poly (methyl vinyl ether/maleic acid) monoethyl ester, and poly(methyl vinyl ether/maleic acid) n-butyl ester and mixtures thereof, nicotine oil and at least one alkaline buffering agent;

wherein the orally dissolving film is effective to reduce nicotine cravings within about 10 minutes through transbuccal absorption of nicotine.

6. A method of providing rapid nicotine craving relief to an individual in need thereof by administering to the individual an orally dissolving film formed by the combination of a polymer consisting of an enteric polymer, nicotine oil and at least one alkaline buffering agent;

wherein the orally dissolving film is effective to reduce nicotine cravings within about 10 minutes through transbuccal absorption of nicotine.

7. An orally dissolving film composition formed by the combination of

a polymer consisting of an enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinylacetate phthalate, poly(ethylacrylate -methacrylic acid) copolymer, shellac, hydroxypropyl methylcellulose acetate succinate, poly (methyl vinyl ether/maleic acid) monoethyl ester, and poly(methyl vinyl ether/maleic acid) n-butyl ester and mixtures thereof;

at least one alkaline buffering agent; and

nicotine oil;

wherein the orally dissolving film is effective to reduce nicotine cravings within about 10 minutes through transbuccal absorption of nicotine.

8. A method of reducing or eliminating tobacco consumption by an individual in need thereof by administering to the individual an orally dissolving film formed by the combination of polymer consisting of a pre-neutralized enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinylacetate phthalate, poly(ethylacrylate-methacrylic acid) copolymer, shellac, hydroxypropyl methylcellulose acetate succinate, poly (methyl vinyl ether/maleic acid) monoethyl ester, and poly(methyl vinyl ether/maleic acid) n-butyl ester and mixtures thereof, nicotine oil and at least one alkaline buffering agent;

wherein the orally dissolving film is effective to reduce nicotine cravings within about 10 minutes through transbuccal absorption of nicotine.

9. A method of providing rapid nicotine craving relief to an individual in need thereof by administering to the individual an orally dissolving film formed by the combination of a polymer consisting of a pre-neutralized enteric polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinylacetate phthalate, poly(ethylacrylate -methacrylic acid) copolymer, shellac, hydroxypropyl methylcellulose acetate succinate, poly (methyl vinyl ether/maleic acid) monoethyl ester, and poly(methyl vinyl ether/maleic acid) n-butyl ester and mixtures thereof, nicotine oil and at least one alkaline buffering agent;

wherein the orally dissolving film is effective to reduce nicotine cravings within about 10 minutes through transbuccal absorption of nicotine.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Sep 23, 2024
From: GLAXOSMITHKLINE LLC; HALEON US HOLDINGS LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 068667/0177 →
CHANGE OF NAME Recorded Jan 7, 2014
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 031926/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2006
From: CHAN, SHING YUE; CHEN, LI-LAN; CHETTY, DUSHENDRA J.; LIU, JOHN JIANGNAN
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 017777/0420 →
Continuity (2)
Provisional Application 60489855 · Jul 24, 2003
Related Publication 20060198873A1 · Sep 7, 2006